首页> 外文期刊>Pharmaceutical research >Pharmacokinetics and modeling of quercetin and metabolites.
【24h】

Pharmacokinetics and modeling of quercetin and metabolites.

机译:槲皮素和代谢产物的药代动力学和建模。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To determine the pharmacokinetics of quercetin and its glucuronide/sulfate conjugates and to develop a pharmacokinetic model to simultaneously describe their disposition after intravenous and oral administration in rats. METHODS: After oral, intraportal, and intravenous administration of quercetin, serial plasma, urine, and fecal concentrations of quercetin and its conjugates were determined by an HPLC method. Enterohepatic recirculation was evaluated in a linked-rat model as well as after oral administration of bile containing quercetin and its metabolites. Based on the experimental data, a specific compartmental model was developed and validated to describe and predict the plasma concentration-time profiles of quercetin and its conjugates after oral and intravenous administration. RESULTS: Only 5.3% of unchanged quercetin was bioavailable, although the total quercetin absorbed was as high as 59.1%. After oral administration, about 93.3% of quercetin was metabolized in the gut, with only 3.1%metabolized in the liver. No significant enterohepatic recirculation was observed for both quercetin and its conjugated metabolites. The pharmacokinetic model fitted well the observed data of quercetin and its conjugates. CONCLUSIONS: Our study clarifies the relative importance of the gut, liver, and bile in the metabolism and excretion of quercetin and its conjugates. The pharmacokinetic model appears to be suitable for describing the absorption and disposition of the quercetin and its conjugates and may be applicable to other flavonoids that undergo similar pharmacokinetic pathways.
机译:目的:确定槲皮素及其葡糖醛酸苷/硫酸盐结合物的药代动力学,并建立一种药代动力学模型,以同时描述其在大鼠静脉内和口服给药后的处置。方法:口服,槲皮素和静脉内注射槲皮素后,通过HPLC方法测定槲皮素及其结合物的系列血浆,尿液和粪便浓度。在链接大鼠模型中以及口服含槲皮素及其代谢产物的胆汁后,评估了肠肝循环。基于实验数据,开发并验证了特定的区室模型,以描述和预测口服和静脉内给药后槲皮素及其结合物的血浆浓度-时间曲线。结果:虽然吸收的槲皮素总含量高达59.1%,但只有5.3%的槲皮素是可生物利用的。口服后,约93.3%的槲皮素在肠道中代谢,而肝脏中只有3.1%代谢。槲皮素及其结合的代谢物均未见明显的肝肠循环。药代动力学模型很好地拟合了槲皮素及其结合物的观察数据。结论:我们的研究阐明了肠,肝和胆汁在槲皮素及其结合物的代谢和排泄中的相对重要性。药代动力学模型似乎适合于描述槲皮素及其结合物的吸收和处置,并且可能适用于经历类似药代动力学途径的其他类黄酮。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号